Immunwork Spotlight: TE-8214 — A Long-Acting Drug Revolution from “Maltose” to “Aqueous Solution”

In 2025, Immunwork successfully reached key clinical trial milestones for two drug candidates, TE-8105 and TE-8214. In an exclusive interview with Lifestyle Forum, Chairman Tse-Wen Chang highlighted the innovative drug design of TE-8214 and its potential breakthrough applications in clinical settings. Looking ahead to 2026, Immunwork will initiate the next phases of clinical trials for both TE-8214 and TE-8105, continuing to evaluate their therapeutic potential while further optimizing dosing strategies and clinical applications. The interview video: https://youtu.be/fnxQxlp84J4 Related News: https://www.ctwant.com/article/463164/ https://www.styletc.com/article/463152/

The release as fetched from its publisher. immunwork.com ↗